HPV预防性疫苗在预防子宫颈癌中的应用进展

被引：10

作者：

刘昱

祁文娟

魏丽惠

机构：

[1] 北京大学人民医院妇产科

来源：

中国妇产科临床杂志 | 2013年 / 14卷 / 04期

关键词：

人乳头瘤状病毒; 预防性疫苗; 子宫颈癌;

D O I：

暂无

中图分类号：

R737.33 [子宫肿瘤];

学科分类号：

100214 ;

摘要：

目的人乳头瘤病毒的感染与子宫颈癌密切相关。HPV疫苗在预防疫苗相关HPV亚型感染及其所致的宫颈疾病的发生方面备受关注,本文就HPV预防性疫苗在子宫颈癌中的应用进展进行了综述。HPV预防性疫苗可激发机体的CD4+T细胞介导的体液免疫应答,产生高效价的中和抗体IgG,从而使人体获得抵抗其相应亚型的感染。目前全球上市的HPV预防性疫苗共有两种:Gardasil及Cervarix。该两种疫苗对预防相关亚型HPV感染的效力高,在分别经过长达7、6.4年的随访中二者的安全性得到了肯定,但仍有很多问题需要进一步研究。HPV预防性疫苗的问世,有望使病因明确的子宫颈癌成为人类全面预防控制的第一个恶性肿瘤。

引用

页码：378 / 381

页数：4

共 19 条

[1] 2004—2005年中国居民子宫颈癌死亡情况及30年变化趋势 [J].

赵方辉 ;

胡尚英 ;

张思维 ;

陈万青 ;

乔友林 .

中华预防医学杂志, 2010, (05)

[2] Prevalence and Risk Factors for HPV in HIV-Positive Young Women Receiving Their First HPV Vaccination [J].

Kahn, Jessica A. ;

Burk, Robert D. ;

Squires, Kathleen E. ;

Kapogiannis, Bill G. ;

Rudy, Bret ;

Xu, Jiahong ;

Gonin, Rene ;

Liu, Nancy ;

Worrell, Carol ;

Wilson, Craig M. .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2012, 61 (03) :390-399

[3] Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination [J].

Smolen, Kinga K. ;

Gelinas, Laura ;

Franzen, Lisa ;

Dobson, Simon ;

Dawar, Meena ;

Ogilvie, Gina ;

Krajden, Mel ;

Fortuno, Edgardo S., III ;

Kollmann, Tobias R. .

VACCINE, 2012, 30 (24) :3572-3579

[4]

Randomized Trial: Immunogenicity and Safety of Coadministered Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine and Combined Hepatitis A and B Vaccine in Girls[J] . Journal of Adolescent Health . 2012 (1)

[5]

Summary of the Eurogin 2011 conference: Highlighting the recent advances in HPV-related cancers[J] . Alcina F. Nicol,Joseph Monsonego.Gynecologic Oncology . 2011 (2)

[6]

Spotlight on Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil?) in the Prevention of Premalignant Genital Lesions, Genital Cancer, and Genital Warts in Women[J] . Paul McCormack,Elmar Joura.BioDrugs . 2011 (5)

[7]

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study[J] . Lancet Oncology . 2010 (11)

[8]

Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-Adjuvanted Cervical Cancer Vaccine Coadministered With Combined Diphtheria-Tetanus-Acellular Pertussis–inactivated Poliovirus Vaccine to Girls and Young Women[J] . José Garcia-Sicilia,Tino F. Schwarz,Alfonso Carmona,Klaus Peters,Jean-Elie Malkin,Phu M. Tran,Ulrich Behre,Enrique B. Iturbe,Gregory Catteau,Florence Thomas,Kurt Dobbelaere,Dominique Descamps,Gary Dubin.Journal of Adolescent Health . 2010 (2)

[9]

Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines[J] . A. Arguedas,C. Soley,C. Loaiza,G. Rincon,S. Guevara,A. Perez,W. Porras,O. Alvarado,L. Aguilar,A. Abdelnour,U. Grunwald,L. Bedell,A. Anemona,P.M. Dull.Vaccine . 2010 (18)

[10]

An Open-Label, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine Given Concomitantly With Diphtheria, Tetanus, Pertussis, and Poliomyelitis Vaccine in Healthy Adolescents 11 to 17 Years of Age[J] . Timo Vesikari,Pierre Van Damme,Niklas Lindblad,Ulrich Pfletschinger,David Radley,Desmond Ryan,Scott Vuocolo,Richard M. Haupt,Dalya Guris.The Pediatric Infectious Disease Journal . 2010 (4)

← 1 2 →